- ISTOOK: IRS “wants to throw us in jail,” says tea party leader
- Easter woes: Chocolate costs soar, becoming ‘unaffordable’ luxury
- Michaels craft chain confirms hackers hit 3M customers
- Special Forces’ suicide rates hit record levels — casualties of ‘hard combat’
- Many Americans would quickly face financial hardship after losing job, poll shows
- Toronto Mayor Rob Ford thanks supporters at re-election campaign bash
- Texas seizes polygamist Warren Jeffs’ 1,600-acre ranch
- Publisher unveils Hillary Clinton’s new memoir — ‘Hard Choices’
- Britain’s Labour Party hires David Axelrod — but can’t spell his name
- Washington and Lee law students demand ban on Confederate flag, say Gen. Lee was racist
FDA revokes approval of Avastin for breast cancer
WASHINGTON (AP) - The government delivered a blow to some desperate patients Friday as it ruled the blockbuster drug Avastin should no longer be used to treat advanced breast cancer.
Avastin is hailed for treating colon cancer and certain other malignancies. But the Food and Drug Administration said it appeared to be a false hope for breast cancer: Studies haven’t found that it helps those patients live longer or brings enough other benefit to outweigh its dangerous side effects.
“I did not come to this decision lightly,” said the FDA’s commissioner, Dr. Margaret Hamburg. But she said, “Sometimes despite the hopes of investigators, patients, industry and even the FDA itself, the results of rigorous testing can be disappointing.”
Avastin remains on the market to treat certain colon, lung, kidney and brain cancers. Doctors are free to prescribe any marketed drug as they see fit. So even though the FDA formally revoked Avastin’s approval as a breast cancer treatment, women could still receive it _ but their insurers may not pay for it. Some insurers already have quit in anticipation of FDA’s long-expected ruling.
However, “Medicare will continue to cover Avastin,” said Brian Cook, spokesman for the Centers for Medicare & Medicaid Services. The agency “will monitor the issue and evaluate coverage options as a result of action by the FDA but has no immediate plans to change coverage policies.”
Including infusion fees, a year’s treatment with Avastin can reach $100,000.
The ruling disappointed patients who believe Avastin is helping to curb their incurable cancer.
“It’s saved my life,” said a tearful Sue Boyce, 54, of Chicago. She’s taken Avastin in addition to chemotherapy since joining a research study in 2003. Her breast cancer eventually spread to her lungs, liver and brain, but Boyce says she is stable and faring well.
“So I’m hoping the insurance company will grandfather me in to continue taking it,” she said.
The Avastin saga began in 2008, when an initial study suggested the drug could delay tumor growth for a few months in women whose breast cancer had spread to other parts of the body. Over the objection of its own advisers and to the surprise of cancer groups, FDA gave Avastin conditional approval _ it could be sold for such women while manufacturer Genentech tried to prove it really worked.
The problem: Ultimately, the tumor effect was even smaller than first thought. Across repeated studies, Avastin patients didn’t live longer or have a higher quality of life. Yet the drug causes some life-threatening risks, including severe high blood pressure, massive bleeding, heart attack or heart failure and tears in the stomach and intestines, the FDA concluded. In two public hearings _ one last year and one this summer _ FDA advisers urged the agency to revoke that approval.
“The science is clear: Breast cancer patients are more likely to be harmed than helped by Avastin,” said Diana Zuckerman of the National Research Center for Women and Families in Washington.
Genentech had argued the drug should remain available while it conducted more research to see if certain subsets of breast cancer patients might benefit, and some patients and their doctors had argued passionately for the drug.
“There certainly are patients who benefit tremendously,” said Boyce’s oncologist, Dr. Melody Cobleigh of Rush University Medical Center. “We’ll just be battling with the insurance companies.”
“For those not fortunate enough to be on Medicare or an insurance plan that covers it, it’s a death sentence,” Christi Turnage of Madison, Miss., said of the FDA’s decision. Her breast cancer had moved into her lungs before she began Avastin three years ago and the spreading stopped, but Turnage said her insurer is ending coverage and she will seek financial help from Genentech’s access program.
TWT Video Picks
- Harry Reid blasts Bundy ranch supporters as 'domestic terrorists'
- Immigration still on hold: Boehner's office
- Inside China: Marine's comment on islands draws sharp Chinese response
- Supreme Court weighs appeal to concealed-carry gun laws
- Prosecutors seek arrest warrant for ferry captain in South Korea
- PRUDEN: When a bored president just 'mails it in'
- With pot and e-cigarettes, Big Tobacco is just waiting to inhale emerging markets
- Army goes to war with National Guard, seizes Apache attack helicopters
- CBO shows it's Paul Ryan 4, Obama 0 on budget targeting
- CARSON: Recovering Tocqueville's vision of American exceptionalism
Top 10 handguns in the U.S.